Watch BHIC. Know when insiders buy.
One email the day a filing lands. Free.
BHIC
BioScience Health Innovations, Inc.
5.50
+0.50 +10.00%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $64.6MP/E —DIV YIELD —FCF YIELD —REV TTM $4.5M +7.8%NET INCOME −$658K −169.2%NET CASH —52W 1.75 – 6.47SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1M | −41.0% | 63.6% | −$218K | −$186K | −140.6% | -0.02 | −$542K | — | — | Aug 7 |
| Q1 2026 · Mar 31 | $751K | −38.8% | 64.7% | −$230K | −$230K | −153.9% | -0.02 | −$552K | — | — | Aug 7 |
| Q4 2025 · Dec 31derived | $1.6M | +157.7% | 36.4% | −$157K | −$234K | −2446.4% | -0.02 | −$101K | — | — | Aug 7 |
| Q3 2025 · Sep 30 | $1.1M | +97.5% | 61.7% | −$9K | −$9K | −115.6% | 0.00 | −$340K | — | — | Oct 27 |
| Q2 2025 · Jun 30 | $1.8M | +357.5% | 61.1% | $458K | $458K | +516.7% | 0.04 | $285K | — | — | Aug 7 |
| Q1 2025 · Mar 31 | $1.2M | +342.0% | 73.0% | $427K | $427K | — | 0.01 | $328K | — | — | Aug 7 |
| Q4 2024 · Dec 31derived | $610K | +101.0% | 55.6% | $10K | $10K | — | 0.00 | −$50K | — | — | Mar 30 |
| Q3 2024 · Sep 30 | $573K | +198.2% | 74.1% | $56K | $56K | — | 0.01 | $52K | — | — | Oct 27 |
| Q2 2024 · Jun 30 | $384K | — | 80.8% | $74K | $74K | — | 0.00 | $69K | — | — | Oct 27 |
| Q1 2024 · Mar 31 | $278K | — | 84.6% | −$53K | −$53K | — | 0.00 | −$48K | — | — | Oct 27 |
| Q4 2023 · Dec 31derived | $304K | — | 77.9% | −$38K | −$38K | — | 0.00 | −$56K | — | — | Mar 13 |
| Q3 2023 · Sep 30 | $192K | — | 83.4% | −$57K | −$57K | — | 0.00 | −$70K | — | — | Oct 28 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $5.7M | 57.0% | $719K | $642K | 11.3% | 0.06 | $172K | — | — | — | — |
| FY2024 · to Dec 31 | $1.8M | 70.9% | $87K | $87K | 4.7% | 0.01 | $23K | — | — | — | — |
| FY2023 · to Dec 31 | $598K | 81.1% | −$252K | −$252K | -42.1% | -0.01 | −$308K | — | — | — | — |
| FY2022 · to Dec 31 | $69K | 86.0% | −$170K | −$170K | -245.8% | — | −$183K | — | — | — | — |
| FY2022 · to Aug 31 | $0 | — | −$92K | −$83K | — | — | −$86K | — | — | — | — |
| FY2021 · to Aug 31 | $0 | — | −$26K | −$26K | — | 0.00 | −$29K | — | — | — | — |
Every number comes from BioScience Health Innovations, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.